Florian Simon

Florian Simon

Auto-generated profile, based on publicly available information

Florian Simon

EnGenes Biotech GmbH, Vienna, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
FSFlorian Simon
Florian Simon
PSPatrick Stargardt
Patrick Stargardt
NDNatalia Danielewicz
Natalia Danielewicz
FWFlorian Weiß
Florian Weiß
JBJohanna Berein
Johanna Berein
JMJuergen Mairhofer
Juergen Mairhofer
Continuous two-stage E. coli fermentations offer potential for high-efficiency bioprocesses but are often limited by plasmid instability, genetic mutations

29 April 2026 in Trends in Biotechnology
Verified
Journal Article
Open access
PSPatrick Stargardt
Patrick Stargardt
ALAnne Ljungars
Anne Ljungars
DSDavid Scheich
David Scheich
Nico LinggNico Lingg
Nico Lingg
EEEmil S. Elmose
Emil S. Elmose
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Oligoclonal VHH mixtures targeting distinct epitopes offer therapeutic benefits in mitigating complex diseases, including cancer, infectious diseases, and snakebite envenoming. However, current production strategies rely on separate expression and purification of individual VHHs, followed by downstream mixing, resulting in high costs. We present a cocultivation approach for producing an experimental recombinant antivenom using growth-decoupled Escherichia coli strains. Six different cell lines were generated by transforming the same host with different VHH genes. The cell lines displayed high-yield extracellular secretion in microtiter plate and 1-l bioreactor cultivations, and cocultivation at defined inoculation ratios yielded oligoclonal VHH mixtures approaching target compositions. This strategy enables one-pot manufacturing with minimal downstream processing and predictable composition. A techno-economic assessment based on obtained titers and two-step purification indicates reduced per-treatment costs compared with Chinese Hamster Ovary cells produced IgG-based antivenoms. Our findings offer an alternative to conventional oligoclonal VHH production for multivalent therapeutics requiring broad neutralization, including recombinant antivenoms.

7 October 2026 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
FSFlorian Simon
Florian Simon
MBMarkus C. Berg
Markus C. Berg
PSPatrick Stargardt
Patrick Stargardt
NDNatalia Danielewicz
Natalia Danielewicz
FWFlorian Weiß
Florian Weiß
JMJuergen Mairhofer
Juergen Mairhofer
Background: Continuous biomanufacturing is increasingly recognized for its potential to improve sustainability, efficiency, and production continuity in manufacturing of biologics. However, its implementation for the production of recombinant proteins in microbial systems, particularly Escherichia coli , remains limited by persistent challenges, including genetic instability, limited secretion capacity, and process heterogeneity. These constraints have so far impeded the development of robust and scalable continuous E. coli -based production platforms. Results: Here, we demonstrate the development of a fully integrated, continuous, digitally controlled and automated biomanufacturing platform utilizing E. coli as microbial production host. As model protein, recombinantly expressed Protein A was used, which was released into the culture supernatant. The end-to-end system comprises upstream cultivation, continuous primary recovery, multi-column chromatography, advanced process automation, and model-based control. The upstream module employs a two-stage chemostat using a genetically engineered and stabilized strain, achieving robust long-term productivity (> 500 h), genetic stability, and minimal cell lysis during Protein A production. An intensified Design of Experiments (iDoE) strategy enabled efficient screening of the design space in a single continuous fermentation, allowing determination of process conditions associated with the highest Protein A titers. Downstream, the culture supernatant was continuously collected by removing cells via Cleaning in Place (CIP) - enabled microfiltration with vibrating membranes. The clarified supernatant was subsequently subjected to real-time inline product analytics and automated continuous chromatography adapting to dynamic process conditions. A modular digital process twin was developed to enable model-based decision support across the entire process chain. The modeling architecture integrates time-resolved sensor data with mechanistic mass-balance relationships to describe dynamic behavior across upstream and downstream unit operations. This framework enabled model-based determination of chromatography switch times by incorporating dynamically varying upstream conditions and inline Protein A measurements. A techno-economic analysis showed 25–39% reductions in capital investment and 26–37% lower operating costs compared to fed-batch strategies, with 45% decrease in facility energy demand. Conclusion: This work represents the first demonstration of a fully digitized continuous E. coli manufacturing platform and provides a scalable blueprint for biomanufacturing transformation. The system offers a modular architecture and demonstrates sustainability benefits, providing a compelling foundation for industrial adoption.